7月15日，Celcuity Inc夜盘下跌5.45%，报105.0美元/股，成交额4229.8美元。
消息面上，FDA正式批准公司核心药物REVTORPYK（gedatolisib）用于HR+/HER2-、PIK3CA野生型局部晚期或转移性乳腺癌，批准基于III期VIKTORIA-1试验数据（中位无进展生存期9.3个月 vs 对照组2.0个月）。然而该股此前已因FDA审评日临近大幅上涨，盘中一度涨超5%，正式获批后资金呈典型"利好兑现"式抛售。此外，当前获批适应症仅限PIK3CA野生型患者，针对PIK3CA突变患者的补充申请尚需于第三季度提交，市场对适应症范围或存在预期差。公司预计将于第三季度末启动商业化。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.